US20170115509A1 - High plus center treatment zone lens design and method for preventing and/or slowing myopia progression - Google Patents

High plus center treatment zone lens design and method for preventing and/or slowing myopia progression Download PDF

Info

Publication number
US20170115509A1
US20170115509A1 US15/383,414 US201615383414A US2017115509A1 US 20170115509 A1 US20170115509 A1 US 20170115509A1 US 201615383414 A US201615383414 A US 201615383414A US 2017115509 A1 US2017115509 A1 US 2017115509A1
Authority
US
United States
Prior art keywords
zone
power
myopia
lens
plus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US15/383,414
Inventor
Noel A. Brennan
Xu Cheng
Michael J. Collins
Brett A. Davis
Jaclyn Hernandez
C. Benjamin Wooley
Fan Yi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Johnson and Johnson Vision Care Inc
Original Assignee
Johnson and Johnson Vision Care Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US14/464,182 external-priority patent/US9638936B2/en
Priority to US15/383,414 priority Critical patent/US20170115509A1/en
Application filed by Johnson and Johnson Vision Care Inc filed Critical Johnson and Johnson Vision Care Inc
Publication of US20170115509A1 publication Critical patent/US20170115509A1/en
Assigned to JOHNSON & JOHNSON VISION CARE, INC. reassignment JOHNSON & JOHNSON VISION CARE, INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: DAVIS, BRETT A., YI, FAN, COLLINS, MICHAEL J., CHENG, XU, HERNANDEZ, JACLYN, BRENNAN, NOEL A., WOOLEY, C. BENJAMIN
Priority to IL255609A priority patent/IL255609A0/en
Priority to AU2017261563A priority patent/AU2017261563B2/en
Priority to SG10201709641QA priority patent/SG10201709641QA/en
Priority to CA2989354A priority patent/CA2989354C/en
Priority to TW106144094A priority patent/TWI767965B/en
Priority to KR1020170173313A priority patent/KR20180071177A/en
Priority to BR102017027278-8A priority patent/BR102017027278A2/en
Priority to RU2017144173A priority patent/RU2694777C2/en
Priority to JP2017241480A priority patent/JP2018101133A/en
Priority to EP17208227.3A priority patent/EP3336600A1/en
Priority to CN202311381706.2A priority patent/CN117434748A/en
Priority to CN201711381406.9A priority patent/CN108205208A/en
Priority to HK18114270.2A priority patent/HK1255154A1/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • GPHYSICS
    • G02OPTICS
    • G02CSPECTACLES; SUNGLASSES OR GOGGLES INSOFAR AS THEY HAVE THE SAME FEATURES AS SPECTACLES; CONTACT LENSES
    • G02C7/00Optical parts
    • G02C7/02Lenses; Lens systems ; Methods of designing lenses
    • G02C7/024Methods of designing ophthalmic lenses
    • GPHYSICS
    • G02OPTICS
    • G02CSPECTACLES; SUNGLASSES OR GOGGLES INSOFAR AS THEY HAVE THE SAME FEATURES AS SPECTACLES; CONTACT LENSES
    • G02C7/00Optical parts
    • G02C7/02Lenses; Lens systems ; Methods of designing lenses
    • G02C7/04Contact lenses for the eyes
    • G02C7/041Contact lenses for the eyes bifocal; multifocal
    • G02C7/044Annular configuration, e.g. pupil tuned
    • GPHYSICS
    • G02OPTICS
    • G02CSPECTACLES; SUNGLASSES OR GOGGLES INSOFAR AS THEY HAVE THE SAME FEATURES AS SPECTACLES; CONTACT LENSES
    • G02C7/00Optical parts
    • G02C7/02Lenses; Lens systems ; Methods of designing lenses
    • G02C7/04Contact lenses for the eyes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/02Prostheses implantable into the body
    • A61F2/14Eye parts, e.g. lenses, corneal implants; Implanting instruments specially adapted therefor; Artificial eyes
    • A61F2/145Corneal inlays, onlays, or lenses for refractive correction
    • A61F2/1451Inlays or onlays
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/02Prostheses implantable into the body
    • A61F2/14Eye parts, e.g. lenses, corneal implants; Implanting instruments specially adapted therefor; Artificial eyes
    • A61F2/16Intraocular lenses
    • A61F2/1613Intraocular lenses having special lens configurations, e.g. multipart lenses; having particular optical properties, e.g. pseudo-accommodative lenses, lenses having aberration corrections, diffractive lenses, lenses for variably absorbing electromagnetic radiation, lenses having variable focus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F9/00Methods or devices for treatment of the eyes; Devices for putting-in contact lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
    • GPHYSICS
    • G02OPTICS
    • G02CSPECTACLES; SUNGLASSES OR GOGGLES INSOFAR AS THEY HAVE THE SAME FEATURES AS SPECTACLES; CONTACT LENSES
    • G02C7/00Optical parts
    • G02C7/02Lenses; Lens systems ; Methods of designing lenses
    • G02C7/04Contact lenses for the eyes
    • G02C7/041Contact lenses for the eyes bifocal; multifocal
    • GPHYSICS
    • G02OPTICS
    • G02CSPECTACLES; SUNGLASSES OR GOGGLES INSOFAR AS THEY HAVE THE SAME FEATURES AS SPECTACLES; CONTACT LENSES
    • G02C7/00Optical parts
    • G02C7/02Lenses; Lens systems ; Methods of designing lenses
    • G02C7/04Contact lenses for the eyes
    • G02C7/041Contact lenses for the eyes bifocal; multifocal
    • G02C7/042Simultaneous type
    • GPHYSICS
    • G02OPTICS
    • G02CSPECTACLES; SUNGLASSES OR GOGGLES INSOFAR AS THEY HAVE THE SAME FEATURES AS SPECTACLES; CONTACT LENSES
    • G02C7/00Optical parts
    • G02C7/02Lenses; Lens systems ; Methods of designing lenses
    • G02C7/04Contact lenses for the eyes
    • G02C7/048Means for stabilising the orientation of lenses in the eye
    • GPHYSICS
    • G02OPTICS
    • G02CSPECTACLES; SUNGLASSES OR GOGGLES INSOFAR AS THEY HAVE THE SAME FEATURES AS SPECTACLES; CONTACT LENSES
    • G02C7/00Optical parts
    • G02C7/02Lenses; Lens systems ; Methods of designing lenses
    • G02C7/06Lenses; Lens systems ; Methods of designing lenses bifocal; multifocal ; progressive
    • GPHYSICS
    • G02OPTICS
    • G02CSPECTACLES; SUNGLASSES OR GOGGLES INSOFAR AS THEY HAVE THE SAME FEATURES AS SPECTACLES; CONTACT LENSES
    • G02C2202/00Generic optical aspects applicable to one or more of the subgroups of G02C7/00
    • G02C2202/24Myopia progression prevention

Definitions

  • the present invention relates to ophthalmic lenses, and more particularly, to contact lenses designed to slow, retard, or prevent myopia progression in the wearer.
  • the ophthalmic lenses of the present invention comprise a high plus or high ADD treatment zone, thereby preventing and/or slowing myopia progression.
  • myopia and hyperopia for which corrective lenses in the form of spectacles, or rigid or soft contact lenses, are prescribed.
  • the conditions are generally described as the imbalance between the length of the eye and the focus of the optical elements of the eye.
  • Myopic eyes focus in front of the retinal plane and hyperopic eyes focus behind the retinal plane.
  • Myopia typically develops because the axial length of the eye grows to be longer than the focal length of the optical components of the eye, that is, the eye grows too long.
  • Hyperopia typically develops because the axial length of the eye is too short compared with the focal length of the optical components of the eye, that is, the eye does not grow enough.
  • Myopia has a high prevalence rate in many regions of the world. Of greatest concern with this condition is its possible progression to high myopia, for example greater than five (5) or six (6) diopters, which dramatically affects one's ability to function without optical aids. High myopia is also associated with an increased risk of retinal disease, cataracts, and glaucoma.
  • Corrective lenses are used to alter the gross focus of the eye to render a clearer image at the retinal plane, by shifting the focus from in front of the plane to correct myopia, or from behind the plane to correct hyperopia, respectively.
  • the corrective approach to the conditions does not address the cause of the condition, but is merely prosthetic or symptomatic.
  • myopia and hyperopia are used to include simple myopia or myopic astigmatism and hyperopia and hyperopic astigmatism respectively.
  • Emmetropia describes the state of clear vision where an object at infinity is in relatively sharp focus with the crystalline lens relaxed.
  • light from both distant and close objects and passing though the central or paraxial region of the aperture or pupil is focused by the crystalline lens inside the eye close to the retinal plane where the inverted image is sensed.
  • D Diopters
  • the measure D is the dioptric power, defined as the reciprocal of the focal distance of a lens or optical system, in meters.
  • the spherical aberration of the normal eye is not constant.
  • accommodation the change in optical power of the eye derived primarily though change to the internal crystalline lens
  • myopia typically occurs due to excessive axial growth or elongation of the eye. It is now generally accepted, primarily from animal research, that axial eye growth can be influenced by the quality and focus of the retinal image. Experiments performed on a range of different animal species, utilizing a number of different experimental paradigms, have illustrated that altering retinal image quality can lead to consistent and predictable changes in eye growth.
  • retinal image quality can influence eye growth.
  • a variety of different ocular conditions, all of which lead to a disruption in form vision, such as ptosis, congenital cataract, corneal opacity, vitreous hemorrhage and other ocular diseases, have been found to be associated with abnormal eye growth in young humans, which suggests that relatively large alterations in retinal image quality do influence eye growth in human subjects.
  • the influence of more subtle retinal image changes on eye growth in humans has also been hypothesized based on optical errors in the human focusing system during near work that may provide a stimulus for eye growth and myopia development in humans.
  • One of the risk factors for myopia development is near work. Due to accommodative lag or negative spherical aberration associated with accommodation during such near work, the eye may experience hyperopic blur, which in turn stimulates myopia progression as discussed above.
  • the accommodation system is an active adaptive optical system; it constantly reacts to near-objects, as well as optical designs. No matter what optical designs one puts on the eye, when the eye accommodates to near-objects, continuous hyperopic defocus will be present and make the eye myopic. Therefore, one way to design optics to slow the rate of myopia progression is to utilize a high plus signal to the retina through use of high ADD or plus powers.
  • U.S. Pat. No. 6,045,578 discloses that the addition of positive spherical aberration on the contact lens will reduce or control the progression of myopia.
  • the method includes changing the spherical aberration of an ocular system by a direction and degree related to alter the growth in eye length, in other words emmetropization may be regulated by spherical aberration.
  • the cornea of a myopic eye is fitted with a lens having increasing dioptric power away from the lens center. Paraxial light rays entering the central portion of the lens are focused on the retina of the eye, producing a clear image of an object.
  • Marginal light rays entering the peripheral portion of the cornea are focused in a plane between the cornea and the retina, and produce positive spherical aberration of the image on the latter.
  • This positive spherical aberration produces a physiological effect on the eye which tends to inhibit growth of the eye, thus mitigating the tendency for the myopic eye to grow longer.
  • Treatment efficacy is defined as the relative change of axial length and/or spherical equivalent refraction from baseline for a test group compared to the change of axial length and/or spherical equivalent refraction of a control group over a year or a predetermined time period.
  • the graph illustrates a device with a design that incorporates a distance zone to correct for distance vision and a peripheral zone of variable plus power.
  • Visual acuity was measured using a four forced choice method with progressively smaller Snellen optotypes.
  • Increasing peripheral plus power to about +2.00 D to +3.00 D causes an increasing loss of high contrast visual acuity, as typical of multifocal type designs for presbyopes.
  • the peripheral power continues to increase; however, the relative effect on visual acuity surprisingly improves and plateaus, so that by above about +4.00 D to +5.00 D peripheral plus, the visual acuity loss becomes relatively constant. This is of significance for the design of myopia control lenses, since higher plus power is found (with animal models) to have a greater impact on eye growth, as reported in Wildsoet & Wallman, Vision Research 1995.
  • power profiles are illustrated having +5.00 D or +10.00 D power beyond a 2.25 mm radial location from a center of a lens. Rays passing through these high plus or high ADD power regions form sharp foci in front of the retina. However, due to continued propagation to the retina, these rays form a ring-like defocus blur on the retina.
  • FIG. 4 the image cross section for the +5.00 D and +10.00 D power profiles of FIG. 2 at an entrance pupil size of 6.0 mm are shown by convolving the PSF with a black/white edge in object space.
  • a lens having 0.00 D power forms a sharp edge between the black and white (at 0.0 mm location) and thus does not have a halo-like structure.
  • the lenses with +5.00 D and +10.00 D regions do not have a sharp edge between black and white, thereby resulting in images in which the black background is not completely black, and the white background is not completely white at the ‘edge’ in the image.
  • halo is an inherent property of high plus or high ADD lens designs.
  • the present invention is directed to lenses having high plus power treatment zones that are suitable for the use in treating, controlling, or reducing the progression of myopia while also minimizing a halo effect.
  • the lens design of the present invention overcomes the limitations of the prior art by providing lenses that ensure distance vision correction and have high plus power treatment zones that treat, control, or reduce the progression of myopia while also minimizing a halo effect.
  • the present invention is directed to an ophthalmic lens for at least one of slowing, retarding or preventing myopia progression and for minimizing a halo effect.
  • the ophthalmic lens comprises an optic zone, the optic zone including a center zone configured as a myopia progression treatment zone, the center zone comprising an ADD power of between +0.5 diopters and +20.0 diopters relative to the negative power required to correct myopia, and at least one peripheral zone surrounding the center zone, the at least one peripheral zone comprising a myopia vision correction region with a negative power for myopic vision correction; and an outer zone surrounding the optic zone.
  • the ophthalmic lens comprises a center zone with high plus power as a myopic progression treatment zone.
  • High plus power has the same meaning as high ADD power and does not necessarily result in a high positive power in the treatment zone as is the case, say, of vision correction of high hyperopia. Rather it refers to a difference in power between the treatment zone and the myopic vision correction zone that is higher than traditionally used for the reading addition powers classically used in bifocal, multifocal or progressive addition lenses for presbyopia.
  • the contact lens comprises an optic zone and an outer zone.
  • the optic zone comprises a center zone and a first peripheral zone. In other embodiments, a different number of zones may be present as is explained in detail subsequently.
  • the center zone has a diameter that ranges from 0.50 mm to 4.00 mm with a power ranging from +5 diopters to +15 diopters.
  • the power can be lower, for example, +2.5 diopters and higher, for example +20 diopters.
  • the first peripheral zone has a negative power for myopic vision correction. In other words, the power to correct the individual's refractive error, myopia, resides in the first peripheral zone rather than in the center of the lens.
  • the contact lens may include one or more additional plus powered concentric treatment zones outside of the first peripheral zone. For example, low plus center zone and higher plus peripheral zones or high plus center zone with lower plus peripheral zones.
  • the first peripheral zone which has the power to correct the refractive error is surrounded with plus power treatment zones. It is important to note that each of the treatment zones may have the same plus power or different plus powers.
  • the diameter of the first peripheral zone and the one or more additional plus powered concentric treatment zones is selected to provide a balance between adequate vision and myopia control treatment. It will be readily apparent to those skilled in the art that the peripheral zone diameters will be chosen depending on the diameter of the central zone to achieve a balance between obtaining adequate myopia control and vision. For example, in a preferred embodiment, the diameter of the central zone is 1.0 mm, the outer diameter of the first peripheral zone is 2.6 mm, and the outer diameter of the second peripheral zone is 3.6 mm. In that example, there may be additional peripheral zones within the optic zone past 3.6 mm.
  • the high plus contact lens design of the present invention provides a simple, cost-effective and efficacious means and method for preventing and/or slowing myopia progression which is increasing throughout the world.
  • FIG. 1 illustrates a graph showing changes in visual acuity as plus power is added in a peripheral zone.
  • FIG. 2 illustrates power profiles of two lenses, one having a +5.00 D treatment zone and the other having a +10.00 D treatment zone.
  • FIG. 3 illustrates a cross section of the point spread function for the power profiles of FIG. 2 at an entrance pupil size of 6.0 mm.
  • FIG. 4 illustrates an image cross section of the power profiles of FIG. 2 .
  • FIG. 5 a illustrates a point spread function for five power profiles.
  • FIG. 5 b illustrates the image cross section of the power profiles of FIG. 5 a.
  • FIGS. 6 a - c illustrates power profiles of three lenses according to the present invention.
  • FIGS. 7 a -c illustrates the image cross section of the power profiles of FIGS. 6 a - c, respectively.
  • FIGS. 8 a - c illustrates power profiles of three additional lenses according to the present invention.
  • FIG. 9 is a diagrammatic representation of an exemplary contact lens in accordance with the present invention.
  • FIG. 10 is a diagrammatic representation of a first alternative exemplary contact lens in accordance with the present invention.
  • FIG. 11 is a diagrammatic representation of a second alternative exemplary contact lens in accordance with the present invention.
  • FIG. 12 is a graphical representation of the loss in visual acuity versus central zone size (i.e. diameter) over four ADD powers for a 5.5 mm pupil size in accordance with the present invention.
  • FIG. 13 is a graphical representation of the loss in visual acuity versus central zone diameter in a lens with a center plus design having a +10 diopter power for both a 5.5 mm pupil and a 3.5 mm pupil in accordance with the present invention.
  • FIG. 14 is a graphical representation of the size of halo in degrees versus central zone diameter in a lens with a center plus design having a +10 diopter power for both a 5.5 mm pupil and a 3.5 mm pupil in accordance with the present invention.
  • FIG. 15 is a graphical representation of the halo brightness versus central zone diameter in a lens with a center plus design having a +10 diopter power for both a 5.5 mm pupil and a 3.5 mm pupil in accordance with the present invention.
  • FIGS. 16A-16D illustrate various exemplary power profiles in accordance with the present invention.
  • an ophthalmic lens has at least one high plus or high ADD treatment zone surrounding a center zone for treating, preventing, or slowing myopia progression while also minimizing any halo effect at a black/white edge.
  • ophthalmic lenses are described with center plus designs and are described with respect to FIG. 10 and beyond.
  • FIG. 5 a (inset graph), five power profiles are illustrated: 1) a power profile having a +5.00 D treatment zone; 2) a power profile having a +10.00 D treatment zone; 3) two zig-zag or sawtooth power profiles with periodic power modulation between about +5.00 D and about +12 D; and 4) a power profile having a gradual power increase from +5.00 D to +12.00 D.
  • the two ring spikes of the +5.00 D and +10.00 D ADD power profiles have a much higher intensity than the other three power profiles, because the latter three designs have continuous power modulation.
  • the latter three designs carry wider ring spikes.
  • the convolution between the spikes with wider width and lower intensity yields a smooth transition of halo intensity between black and white edges, as shown in FIG. 5 b (inset graph), as compared to the sharp edges for the +5.00 D and +10.00 D power profiles, as shown in the main graph of FIG. 5 b .
  • the smooth transition human vision finds any halo effect for the latter three power profiles less bothersome than the halo effect resulting from the abrupt intensity profiles.
  • the power profile comprises a center zone, which may have a negative focal power to correct existing a myopic distance vision condition (i.e., paraxial power).
  • the diameter of the center zone may be about 3 mm to about 7 mm, for example 4.3 mm.
  • Each lens design also comprises at least one treatment zone that surrounds the center zone. The at least one treatment zone carries a large amount of high ADD or high plus power relative to the power in the center zone.
  • the power profiles rise gradually and continuously from a margin of the center zone (point A) to a point within the at least one treatment zone (point B).
  • the location of point B is between 3.0 mm and 4.5 mm from a center of the lens.
  • the at least one treatment zone may remain constant from point B to a margin of an optic zone (point C, for example at 4.5 mm).
  • the power profile may zig-zag or oscillate as the power rises from point A to point B and/or point C and does not need to be monotonic.
  • the at least one treatment zone may have a dioptric power ranging from about +1 D to about +15 D.
  • a gradual and/or periodic change of plus power in the at least one treatment zone mitigates the halo effect because such variations smoothen the intensity profile at sharp black and white edges.
  • the halo intensity profiles of the three lens designs of FIGS. 6 a - c are shown in FIGS. 7 a - c, respectively. All three designs have a smooth halo intensity profile at the black/white edge.
  • lenses of the present invention are designed so that the halo becomes less bothersome to the human eye, it may be difficult to reduce the halo effect when the lens becomes decentered on the eye.
  • the ring-like structure in PSF becomes asymmetric, and energy will shift from one side of PSF to another side.
  • one side of ring-like structure in PSF will have a much higher intensity, and the halo intensity will increase.
  • the halo will become obvious regardless to the halo intensity profile.
  • the utilized lens geometrical design should preferably result in good lens centration on the eye to further minimize potential for the visual artifacts.
  • FIGS. 8 a - c the power profiles for three additional lens designs according to the present invention are illustrated.
  • These three lens designs have 1) at least one enhanced treatment zone in which power is added within the center zone, and 2) at least one treatment zone.
  • the at least one enhanced treatment zone may vary in diameter from about 0.5 mm to about 1.0 mm.
  • the power magnitude of the at least one enhanced treatment zone may range from about +1 D ( FIG. 8 a ) to about +10 D ( FIGS. 8 b - c ).
  • the at least one treatment zone have a gradual and/or period change in plus or ADD power as discussed above or may have a stepped increase in plus or ADD power.
  • the power magnitude of the at least one treatment zone may range from about +5 D to about +15 D ( FIGS. 8 b - c ).
  • the contact lens 900 comprises an optic zone 902 and an outer zone 904 .
  • the optic zone 902 comprises a first, center zone 906 and at least one peripheral zone 908 .
  • the diameter of the optic zone 902 may be selected to be 8.0 mm
  • the diameter of the substantially circular first zone 906 may be selected to be 4.0 mm
  • the boundary diameters of an annular outer peripheral zone 908 may be 5 mm and 6.5 mm as measured from the geometric center of the lens 900 . It is important to note that FIG. 9 only illustrates an exemplary embodiment of the present invention.
  • the outer boundary of the at least one peripheral zone 908 does not necessarily coincide with the outer margin of the optic zone 902 , whereas in other exemplary embodiments, they may coincide.
  • the outer zone 904 surrounds the optic zone 902 and provides standard contact lens features, including lens positioning and centration.
  • the outer zone 904 may include one or more stabilization mechanisms to reduce lens rotation when on eye.
  • zones in FIG. 9 are illustrated as concentric circles, the zones may comprise any suitable round or non-round shapes such as an elliptical shape.
  • the lens design may be customized to achieve both good foveal vision correction and myopic treatment efficacy based on the patient's average pupil size.
  • the lens may be further optimized towards subgroups of the pediatric subpopulation with specific age and/or refraction based upon their pupil sizes.
  • the power profiles may be adjusted or tailored to pupil size to achieve an optimal balance between foveal vision correction and minimization of halo effect resulting from a high plus or high ADD treatment zone.
  • contact lenses remain a cost effective means for vision correction.
  • the thin plastic lenses fit over the cornea of the eye to correct vision defects, including myopia or nearsightedness, hyperopia or farsightedness, astigmatism, i.e. asphericity in the cornea, and presbyopia, i.e., the loss of the ability of the crystalline lens to accommodate.
  • Contact lenses are available in a variety of forms and are made of a variety of materials to provide different functionality.
  • Daily wear soft contact lenses are typically made from soft polymer materials combined with water for oxygen permeability.
  • Daily wear soft contact lenses may be daily disposable or extended wear disposable. Daily disposable contact lenses are usually worn for a single day and then thrown away, while extended wear or frequent replacement disposable contact lenses are usually worn for a period of up to thirty days.
  • Colored soft contact lenses use different materials to provide different functionality. For example, a visibility tint contact lens uses a light tint to aid the wearer in locating a dropped contact lens, enhancement tint contact lenses have a translucent tint that is meant to enhance one's natural eye color, the color tint contact lens comprises a darker, opaque tint meant to change one's eye color, and the light filtering tint contact lens functions to enhance certain colors while muting others.
  • Rigid gas permeable hard contact lenses are made from siloxane-containing polymers but are more rigid than soft contact lenses and thus hold their shape and are more durable.
  • Bifocal contact lenses are designed specifically for patients with presbyopia and are available in both soft and rigid varieties.
  • Toric contact lenses are designed specifically for patients with astigmatism and are also available in both soft and rigid varieties.
  • Combination lenses combining different aspects of the above are also available, for example, hybrid contact lenses.
  • the lens designs of the present invention may be incorporated into any number of different contact lenses formed from any number of materials.
  • the lens design of the present invention may be utilized in any of the contact lenses described herein, including, daily wear soft contact lenses, rigid gas permeable contact lenses, bifocal contact lenses, toric contact lenses and hybrid contact lenses.
  • the invention is described with respect to contact lenses, it is important to note that the concept of the present invention may be utilized in spectacle lenses, intraocular lenses, corneal inlays and onlays.
  • an ophthalmic lens comprises a center zone with high plus power as a myopic progression treatment zone.
  • high plus power has the same meaning as high ADD power and does not necessarily result in a high positive power in the treatment zone as is the case, say, of vision correction of high hyperopia. Rather it refers to a difference in power between the treatment zone and the myopic vision correction zone that is higher than traditionally used for the reading addition powers classically used in bifocal, multifocal or progressive addition lenses for presbyopia.
  • FIG. 10 there is illustrated a diagrammatic representation of a contact lens 1000 in accordance with this exemplary embodiment.
  • the contact lens 1000 comprises an optic zone 1002 and an outer zone 1004 .
  • the optic zone 1002 comprises a center zone 1006 and a first peripheral zone 1008 .
  • the center zone 1006 has a diameter that ranges from 0.50 mm to 4.0 mm with a power ranging from +5 diopters to +15 diopters. In other embodiments, the power can be lower, for example, +2.5 diopters and higher, for example +20 diopters.
  • the first peripheral zone 1008 has a negative power for myopic vision correction. In other words, the power to correct the individual's refractive error, myopia, resides in the first peripheral zone 1008 rather than in the center of the lens.
  • the contact lens 1000 may include an additional plus powered concentric treatment zones 1010 outside of the first peripheral zone 1008 .
  • the first peripheral zone 1008 which has the power to correct the refractive error is surrounded with plus power treatment zones. It is important to note that each of the treatment zones may have the same plus power or different plus powers.
  • the diameter of the first peripheral zone 1008 and the one or more additional plus powered concentric treatment zones 1010 is selected to provide a balance between adequate vision and myopia control treatment. Additional exemplary zone diameters are illustrated in FIG. 10 . It will be readily apparent to those skilled in the art that the peripheral zone diameters will be chosen depending on the diameter of the central zone to achieve a balance between obtaining adequate myopia control and satisfactory vision. For example, in a preferred embodiment, the diameter of the central zone is 1.0 mm, the outer diameter of the first peripheral zone is 4.2 mm, and the outer diameter of the second peripheral zone is 8.5 mm.
  • the contact lens 1100 comprises an optic zone 1102 and an outer zone 1104 .
  • the optic zone 1102 comprises a center zone 1106 and a first peripheral zone 1108 .
  • the center zone 1106 has a diameter that ranges from 0.50 mm to 4.0 mm with a power ranging from +5 diopters to +15 diopters. In other embodiments, the power may be lower, for example, +2.5 diopters and higher, for example, +20 diopters.
  • the first peripheral zone 1108 has a negative power for myopic vision correction.
  • the contact lens 1100 may include one or more additional plus powered concentric treatment zones 1110 outside of the first peripheral zone 1108 . More specifically, the first peripheral zone 1108 which has the power to correct the refractive error is surrounded with plus power treatment zones. It is important to note that each of the treatment zones may have the same plus power or different plus powers. Contact lens 1100 may include an additional negative power for myopic vision correction zone 1112 .
  • the diameter of the first peripheral zone 1108 , the one or more additional plus powered concentric treatment zones 1110 , and the additional negative power zone 1112 are selected to provide a balance between adequate vision and myopia control treatment. For this exemplary embodiment, refer to FIG. 11 for the range of diameters for the zones.
  • Various embodiments may include a center myopia progression treatment zone in combination with peripheral zones that may be utilized for refractive error correction and additional myopia progression treatment zones all within the peripheral region.
  • Various combinations may be utilized outside of the center zone.
  • Multiple concentric zones for myopic vision correction and treatment with different ADD powers may be added in the peripheral region of the optic zone with the zones so arranged to achieve a balance between myopic control treatment efficacy and adequate vision.
  • the myopia control efficacy of a multi-zone soft contact lens is believed to be related to several factors, including the power of the treatment zone, the size of the treatment zone relative to the entrance pupil, and the proximity of the treatment zone to the geometric center of the contact lens.
  • the challenge of any myopia control treatment is to deliver a high myopia control effect while maintaining acceptable vision.
  • the design of this exemplary embodiment maximizes the power of the treatment zone and the proximity of the treatment zone to the center of the lens while minimizing the size of the treatment zone relative to the entrance pupil to provide for acceptable vision.
  • the contact lens of the present invention comprises a small diameter treatment zone of high plus power in the center of the lens.
  • FIG. 12 there is illustrated a graphical representation of the loss in visual acuity, VA, in logMAR versus central zone size over four ADD powers for a 5.5 mm pupil size.
  • This VA data was generated by introducing the optical designs to the eye. As may be seen from FIG. 12 , minimizing the size of the treatment zone relative to the entrance pupil yields better results relative to the loss of VA. In addition, the data suggest that once a power of +5 diopters or greater is utilized, the rays passing through the treatment zones are sufficiently spread upon reaching the retina that loss in visual acuity is minimized.
  • FIG. 13 is a graphical representation of the loss in visual acuity versus central zone diameter in a lens with a center plus design having a +10 diopter power for both a 5.5 mm pupil and a 3.5 mm pupil.
  • VA decreases as the size of the central plus zone increases.
  • VA is lowered by 0.03+/ ⁇ 0.01, 0.05+/ ⁇ 0.04 and 0.06+/ ⁇ 0.05 logMAR for 1.0, 1.5 and 2.0 mm near zone diameters respectively.
  • the VA is further decreased to 0.07 30 / ⁇ 0.03, 0.08+/ ⁇ 0.04 and 0.14+/ ⁇ 0.01 logMAR compared to the baseline.
  • FIG. 14 is a graphical representation of the size of halo in degrees versus central diameter for both a 5.5 mm diameter pupil and a 3.5 mm diameter pupil.
  • the halo data of a center plus design having a +10 diopter power was generated by introducing the optical designs to the eye and using purpose built methodologies to measure halo size and brightness. As illustrated, halo was not visible for center plus conditions for a 1.0 mm diameter central plus zone. For a 5.5 mm diameter pupil, the halo was detectable for both 1.5 and 2.0 mm diameter central zones, with halo sizes of 0.40+/ ⁇ 0.24 degrees and 0.73+/ ⁇ 0.22 degrees respectively.
  • FIG. 15 is a graphical representation of the brightness of halo versus central zone diameter for both a 5.5 mm diameter pupil and a 3.5 mm diameter pupil. As illustrated, halo is not visible for center plus designs with a 1.00 mm diameter central plus zone. Halo is not detectable for a 1.5 mm center plus design for a 3.5 mm pupil diameter. For a 5.5 mm diameter pupil, the halo was detectable for 1.5 and 2.0 mm diameter central zones with brightness of 13.5+/ ⁇ 2.8 and 16.5+/ ⁇ 6.4 gray level respectively. For a 3.5 mm diameter pupil, the halo was only detectable with a 2.0 mm diameter central zone with a brightness of 15.5+/ ⁇ 2.8 gray level.
  • a center zone has a negative power for myopic vision correction
  • a first peripheral region has a high ADD
  • a second peripheral zone has a negative power for myopic vision correction equal to the center zone.
  • the center zone has a high ADD
  • a first peripheral zone has a negative power for myopic vision correction
  • a second peripheral zone has a high ADD equal to the center zone
  • a third peripheral zone has a negative power for myopic vision correction equal to the first peripheral zone.
  • the center zone has a low Add
  • a first peripheral zone has a negative power for myopic vision correction
  • a second peripheral zone has a high ADD which is higher than the ADD in the center zone and a third peripheral zone has a negative power for myopic vision correction equal to the first peripheral zone.
  • a center zone has a high ADD
  • a first peripheral zone has a negative power for myopic vision correction
  • a second peripheral zone has a low ADD
  • a third peripheral zone has a negative power for myopic vision correction equal to the first peripheral zone.
  • the y-axis power is relative to the negative power for myopic vision correction as is the case for FIG. 2, 6A, 6B, 6C, 8A, 8B, and 8C .

Abstract

Contact lenses incorporate high plus or ADD power profiles that at least one of slow, retard or preventing myopia progression and minimize halo effect. The lens includes a center zone with an ADD power for myopia progression treatment and at least one myopia vision correction power in a peripheral region surrounding the center zone.

Description

    CROSS REFERENCE TO RELATED APPLICATION
  • This patent application is a continuation-in-part of U.S. patent application Ser. No. 14,464,182, filed Aug. 20, 2014.
  • BACKGROUND OF THE INVENTION
  • Field of the Invention
  • The present invention relates to ophthalmic lenses, and more particularly, to contact lenses designed to slow, retard, or prevent myopia progression in the wearer. The ophthalmic lenses of the present invention comprise a high plus or high ADD treatment zone, thereby preventing and/or slowing myopia progression.
  • Discussion of the Related Art
  • Common conditions which lead to reduced visual acuity are myopia and hyperopia, for which corrective lenses in the form of spectacles, or rigid or soft contact lenses, are prescribed. The conditions are generally described as the imbalance between the length of the eye and the focus of the optical elements of the eye. Myopic eyes focus in front of the retinal plane and hyperopic eyes focus behind the retinal plane. Myopia typically develops because the axial length of the eye grows to be longer than the focal length of the optical components of the eye, that is, the eye grows too long. Hyperopia typically develops because the axial length of the eye is too short compared with the focal length of the optical components of the eye, that is, the eye does not grow enough.
  • Myopia has a high prevalence rate in many regions of the world. Of greatest concern with this condition is its possible progression to high myopia, for example greater than five (5) or six (6) diopters, which dramatically affects one's ability to function without optical aids. High myopia is also associated with an increased risk of retinal disease, cataracts, and glaucoma.
  • Corrective lenses are used to alter the gross focus of the eye to render a clearer image at the retinal plane, by shifting the focus from in front of the plane to correct myopia, or from behind the plane to correct hyperopia, respectively. However, the corrective approach to the conditions does not address the cause of the condition, but is merely prosthetic or symptomatic.
  • Most eyes do not have simple myopia or hyperopia, but have myopic astigmatism or hyperopic astigmatism. Astigmatic errors of focus cause the image of a point source of light to form as two mutually perpendicular lines at different focal distances. In the foregoing discussion, the terms myopia and hyperopia are used to include simple myopia or myopic astigmatism and hyperopia and hyperopic astigmatism respectively.
  • Emmetropia describes the state of clear vision where an object at infinity is in relatively sharp focus with the crystalline lens relaxed. In normal or emmetropic adult eyes, light from both distant and close objects and passing though the central or paraxial region of the aperture or pupil is focused by the crystalline lens inside the eye close to the retinal plane where the inverted image is sensed. It is observed, however, that most normal eyes exhibit positive longitudinal spherical aberration, generally in the region of about +0.50 Diopters (D) for a 5.0 mm aperture, meaning that rays passing through the aperture or pupil at its periphery are focused +0.50 D in front of the retinal plane when the eye is focused to infinity. As used herein the measure D is the dioptric power, defined as the reciprocal of the focal distance of a lens or optical system, in meters.
  • The spherical aberration of the normal eye is not constant. For example, accommodation (the change in optical power of the eye derived primarily though change to the internal crystalline lens) causes the spherical aberration to change from positive to negative.
  • As noted, myopia typically occurs due to excessive axial growth or elongation of the eye. It is now generally accepted, primarily from animal research, that axial eye growth can be influenced by the quality and focus of the retinal image. Experiments performed on a range of different animal species, utilizing a number of different experimental paradigms, have illustrated that altering retinal image quality can lead to consistent and predictable changes in eye growth.
  • Furthermore, defocusing the retinal image in both chick and primate animal models, through positive lenses (myopic defocus) or negative lenses (hyperopic defocus), is known to lead to predictable (in terms of both direction and magnitude) changes in eye growth, consistent with the eyes growing to compensate for the imposed defocus. The changes in eye length associated with optical blur have been shown to be modulated by changes in both scleral growth and choroidal thickness. Blur with positive lenses, which leads to myopic blur and decreases scleral growth rate, results in hyperopic refractive errors. Blur with negative lenses, which leads to hyperopic blur and increases scleral growth rate, results in myopic refractive errors. These eye growth changes in response to retinal image defocus have been demonstrated to be largely mediated through local retinal mechanisms, as eye length changes still occur when the optic nerve is damaged, and imposing defocus on local retinal regions has been shown to result in altered eye growth localized to that specific retinal region.
  • In humans there is both indirect and direct evidence that supports the notion that retinal image quality can influence eye growth. A variety of different ocular conditions, all of which lead to a disruption in form vision, such as ptosis, congenital cataract, corneal opacity, vitreous hemorrhage and other ocular diseases, have been found to be associated with abnormal eye growth in young humans, which suggests that relatively large alterations in retinal image quality do influence eye growth in human subjects. The influence of more subtle retinal image changes on eye growth in humans has also been hypothesized based on optical errors in the human focusing system during near work that may provide a stimulus for eye growth and myopia development in humans.
  • One of the risk factors for myopia development is near work. Due to accommodative lag or negative spherical aberration associated with accommodation during such near work, the eye may experience hyperopic blur, which in turn stimulates myopia progression as discussed above. Moreover, the accommodation system is an active adaptive optical system; it constantly reacts to near-objects, as well as optical designs. No matter what optical designs one puts on the eye, when the eye accommodates to near-objects, continuous hyperopic defocus will be present and make the eye myopic. Therefore, one way to design optics to slow the rate of myopia progression is to utilize a high plus signal to the retina through use of high ADD or plus powers.
  • U.S. Pat. No. 6,045,578 discloses that the addition of positive spherical aberration on the contact lens will reduce or control the progression of myopia. The method includes changing the spherical aberration of an ocular system by a direction and degree related to alter the growth in eye length, in other words emmetropization may be regulated by spherical aberration. In this process, the cornea of a myopic eye is fitted with a lens having increasing dioptric power away from the lens center. Paraxial light rays entering the central portion of the lens are focused on the retina of the eye, producing a clear image of an object. Marginal light rays entering the peripheral portion of the cornea are focused in a plane between the cornea and the retina, and produce positive spherical aberration of the image on the latter. This positive spherical aberration produces a physiological effect on the eye which tends to inhibit growth of the eye, thus mitigating the tendency for the myopic eye to grow longer.
  • Although the level of positive spherical aberration and/or plus power required to achieve an optimum slowdown in the myopia progression rate is unclear, researchers in the field have attempted to use multi-zone devices with regions of positive power of about +1.50 to a maximum of +3.00 D ADD in an attempt to slow the progression of myopia. It is important to note that a positive power of up to 4.00 diopters has also been attempted. The approach resulted in treatment results of less than about 50 percent. Treatment efficacy is defined as the relative change of axial length and/or spherical equivalent refraction from baseline for a test group compared to the change of axial length and/or spherical equivalent refraction of a control group over a year or a predetermined time period. There remains a need for a myopia control treatment with efficacy greater than 50 percent and closer to 100 percent. Intuitively adding treatment zones of high plus power would provide greater treatment as the ocular growth response in animals was proportional to the power of the optical stimulus as reported by Wildsoet & Wallman, Vision Research 1995.
  • However, conventional wisdom in the field of bifocal or multifocal ophthalmic lenses assumes lenses with high plus or high ADD power may have deleterious effects on vision and contrast sensitivity as reported by Ardaya et al, Optometry 2004. Further, Smith et al (U.S Pat. No. 7,025,460) teaches against going to powers outside the range normally found in bifocal or multifocal lenses for presbyopia. They state “It is important to note that, while the appropriate type of refractive defocus can drive eye growth (or non-growth) leading to myopia (or its regression) in the phenomenon of lens compensation, when the amount of refractive defocus is great, there may be such a large degradation in image quality due to the severe defocus that the optical state may change into the phenomenon of form deprivation and may induce myopia in that way.” Further, they teach “that the maximum amount of relative curvature of field before substantial vision degradation occurs, which leads to form deprivation myopia, to be around the spherical equivalent of +3.50 D to +4.00 D, which represents the upper limit for negative curvature of field for effective treatment of myopia.” This belief has discouraged researchers from pursuing high plus treatment zones for myopia control.
  • To the contrary, applicant's research shows that using a design with a central distance zone and a high plus or high ADD treatment zone having a plus power greater than about 3.00 D reduces visual acuity loss relative to low conventional plus type designs with no significant additional impact on contrast sensitivity. This is also supported in recent work by De Gracia et el, OVS 2013, although they only investigated up to 4.00 D of ADD power and did not relate the work to a potential benefit in myopia progression control. This breakthrough enables ophthalmic designs to achieve a meaningful greater than 50 percent slowdown in myopia progression without further negatively impacting visual acuity.
  • Further, significantly higher plus power relative to the distance power is not expected to lead to reduced accommodation as may occur with a lower ADD power design where a subject might rely to some extent on the ADD power for clear vision during near work activities, as has been observed during the course of our research. This reduced accommodation may lead to hyperopic defocus of rays passing through the distance portion of the device. In the current invention, the subject must accommodate over the distance portion of the lens for near vision correction as objects imaged through the treatment zones of high plus powers are sufficiently out of focus that they cannot be cleared with the accommodation-convergence system.
  • Another researchers in the field, R. Griffin WO2012/173891, claims to relieve accommodative lag and accommodative stresses that lead to myopia progression through the creation of an artificial pinhole that results in increased depth of focus and depth of field. In their intellectual property, “the eye's accommodation is more relaxed” in contrast to the present invention.
  • With reference now to FIG. 1, the graph illustrates a device with a design that incorporates a distance zone to correct for distance vision and a peripheral zone of variable plus power. Visual acuity was measured using a four forced choice method with progressively smaller Snellen optotypes. Increasing peripheral plus power to about +2.00 D to +3.00 D causes an increasing loss of high contrast visual acuity, as typical of multifocal type designs for presbyopes. As the peripheral power continues to increase; however, the relative effect on visual acuity surprisingly improves and plateaus, so that by above about +4.00 D to +5.00 D peripheral plus, the visual acuity loss becomes relatively constant. This is of significance for the design of myopia control lenses, since higher plus power is found (with animal models) to have a greater impact on eye growth, as reported in Wildsoet & Wallman, Vision Research 1995.
  • However, further optimization of plus power designs is required to optimize image quality. With reference now to FIG. 2, power profiles are illustrated having +5.00 D or +10.00 D power beyond a 2.25 mm radial location from a center of a lens. Rays passing through these high plus or high ADD power regions form sharp foci in front of the retina. However, due to continued propagation to the retina, these rays form a ring-like defocus blur on the retina.
  • As shown in the point spread function (PSF) cross section of FIG. 3, rays coming from the +5.00 D and +10.00 D regions form separate spikes on the retina. Thus, if one looks at a point light source through one of these +5.00 D or +10.00 D high plus lenses, his/her retina would receive a peak signal surrounded by a ring-like halo. Usually, this is not a problem when one reads letters or resolves fine details of objects because the halo is so dim that the human doesn't perceive it. Nevertheless, this is a problem if a person looks at a black/white edge, a white/black edge, a light/dark edge, a dark/light edge and/or any high contrast edge, as energy from the white/black/light background can leak into the black/white/dark due to the presence of the spike in PSF.
  • With reference now to FIG. 4, the image cross section for the +5.00 D and +10.00 D power profiles of FIG. 2 at an entrance pupil size of 6.0 mm are shown by convolving the PSF with a black/white edge in object space. A lens having 0.00 D power forms a sharp edge between the black and white (at 0.0 mm location) and thus does not have a halo-like structure. On the other hand, the lenses with +5.00 D and +10.00 D regions do not have a sharp edge between black and white, thereby resulting in images in which the black background is not completely black, and the white background is not completely white at the ‘edge’ in the image.
  • Accordingly, the presence of halo is an inherent property of high plus or high ADD lens designs. The present invention is directed to lenses having high plus power treatment zones that are suitable for the use in treating, controlling, or reducing the progression of myopia while also minimizing a halo effect.
  • SUMMARY OF THE INVENTION
  • The lens design of the present invention overcomes the limitations of the prior art by providing lenses that ensure distance vision correction and have high plus power treatment zones that treat, control, or reduce the progression of myopia while also minimizing a halo effect.
  • In accordance with one aspect, the present invention is directed to an ophthalmic lens for at least one of slowing, retarding or preventing myopia progression and for minimizing a halo effect. The ophthalmic lens comprises an optic zone, the optic zone including a center zone configured as a myopia progression treatment zone, the center zone comprising an ADD power of between +0.5 diopters and +20.0 diopters relative to the negative power required to correct myopia, and at least one peripheral zone surrounding the center zone, the at least one peripheral zone comprising a myopia vision correction region with a negative power for myopic vision correction; and an outer zone surrounding the optic zone.
  • The ophthalmic lens comprises a center zone with high plus power as a myopic progression treatment zone. High plus power has the same meaning as high ADD power and does not necessarily result in a high positive power in the treatment zone as is the case, say, of vision correction of high hyperopia. Rather it refers to a difference in power between the treatment zone and the myopic vision correction zone that is higher than traditionally used for the reading addition powers classically used in bifocal, multifocal or progressive addition lenses for presbyopia. More specifically, the contact lens comprises an optic zone and an outer zone. The optic zone comprises a center zone and a first peripheral zone. In other embodiments, a different number of zones may be present as is explained in detail subsequently. In this exemplary embodiment, the center zone has a diameter that ranges from 0.50 mm to 4.00 mm with a power ranging from +5 diopters to +15 diopters. In other embodiments, the power can be lower, for example, +2.5 diopters and higher, for example +20 diopters. Also in this exemplary embodiment, the first peripheral zone has a negative power for myopic vision correction. In other words, the power to correct the individual's refractive error, myopia, resides in the first peripheral zone rather than in the center of the lens. The contact lens may include one or more additional plus powered concentric treatment zones outside of the first peripheral zone. For example, low plus center zone and higher plus peripheral zones or high plus center zone with lower plus peripheral zones. More specifically, the first peripheral zone which has the power to correct the refractive error is surrounded with plus power treatment zones. It is important to note that each of the treatment zones may have the same plus power or different plus powers. The diameter of the first peripheral zone and the one or more additional plus powered concentric treatment zones is selected to provide a balance between adequate vision and myopia control treatment. It will be readily apparent to those skilled in the art that the peripheral zone diameters will be chosen depending on the diameter of the central zone to achieve a balance between obtaining adequate myopia control and vision. For example, in a preferred embodiment, the diameter of the central zone is 1.0 mm, the outer diameter of the first peripheral zone is 2.6 mm, and the outer diameter of the second peripheral zone is 3.6 mm. In that example, there may be additional peripheral zones within the optic zone past 3.6 mm.
  • The high plus contact lens design of the present invention provides a simple, cost-effective and efficacious means and method for preventing and/or slowing myopia progression which is increasing throughout the world.
  • BRIEF DESCRIPTION OF THE DRAWINGS
  • The foregoing and other features and advantages of the invention will be apparent from the following, more particular description of preferred embodiments of the invention, as illustrated in the accompanying drawings.
  • FIG. 1 illustrates a graph showing changes in visual acuity as plus power is added in a peripheral zone.
  • FIG. 2 illustrates power profiles of two lenses, one having a +5.00 D treatment zone and the other having a +10.00 D treatment zone.
  • FIG. 3 illustrates a cross section of the point spread function for the power profiles of FIG. 2 at an entrance pupil size of 6.0 mm.
  • FIG. 4 illustrates an image cross section of the power profiles of FIG. 2.
  • FIG. 5a illustrates a point spread function for five power profiles.
  • FIG. 5b illustrates the image cross section of the power profiles of FIG. 5 a.
  • FIGS. 6a-c illustrates power profiles of three lenses according to the present invention.
  • FIGS. 7a -c illustrates the image cross section of the power profiles of FIGS. 6a -c, respectively.
  • FIGS. 8a-c illustrates power profiles of three additional lenses according to the present invention.
  • FIG. 9 is a diagrammatic representation of an exemplary contact lens in accordance with the present invention.
  • FIG. 10 is a diagrammatic representation of a first alternative exemplary contact lens in accordance with the present invention.
  • FIG. 11 is a diagrammatic representation of a second alternative exemplary contact lens in accordance with the present invention.
  • FIG. 12 is a graphical representation of the loss in visual acuity versus central zone size (i.e. diameter) over four ADD powers for a 5.5 mm pupil size in accordance with the present invention.
  • FIG. 13 is a graphical representation of the loss in visual acuity versus central zone diameter in a lens with a center plus design having a +10 diopter power for both a 5.5 mm pupil and a 3.5 mm pupil in accordance with the present invention.
  • FIG. 14 is a graphical representation of the size of halo in degrees versus central zone diameter in a lens with a center plus design having a +10 diopter power for both a 5.5 mm pupil and a 3.5 mm pupil in accordance with the present invention.
  • FIG. 15 is a graphical representation of the halo brightness versus central zone diameter in a lens with a center plus design having a +10 diopter power for both a 5.5 mm pupil and a 3.5 mm pupil in accordance with the present invention.
  • FIGS. 16A-16D illustrate various exemplary power profiles in accordance with the present invention.
  • DETAILED DESCRIPTION OF THE INVENTION
  • In accordance with the present invention, an ophthalmic lens has at least one high plus or high ADD treatment zone surrounding a center zone for treating, preventing, or slowing myopia progression while also minimizing any halo effect at a black/white edge. In accordance with alternate exemplary embodiments, ophthalmic lenses are described with center plus designs and are described with respect to FIG. 10 and beyond.
  • With reference now to FIG. 5a (inset graph), five power profiles are illustrated: 1) a power profile having a +5.00 D treatment zone; 2) a power profile having a +10.00 D treatment zone; 3) two zig-zag or sawtooth power profiles with periodic power modulation between about +5.00 D and about +12 D; and 4) a power profile having a gradual power increase from +5.00 D to +12.00 D.
  • In the PSF cross section of FIG. 5a (main graph), the two ring spikes of the +5.00 D and +10.00 D ADD power profiles have a much higher intensity than the other three power profiles, because the latter three designs have continuous power modulation. On the other hand, the latter three designs carry wider ring spikes. The convolution between the spikes with wider width and lower intensity yields a smooth transition of halo intensity between black and white edges, as shown in FIG. 5b (inset graph), as compared to the sharp edges for the +5.00 D and +10.00 D power profiles, as shown in the main graph of FIG. 5b . As a result of the smooth transition, human vision finds any halo effect for the latter three power profiles less bothersome than the halo effect resulting from the abrupt intensity profiles.
  • With reference now to FIGS. 6a -6 c, the power profiles of three lens designs according to the present invention are illustrated. For each design, the power profile comprises a center zone, which may have a negative focal power to correct existing a myopic distance vision condition (i.e., paraxial power). The diameter of the center zone may be about 3 mm to about 7 mm, for example 4.3 mm. Each lens design also comprises at least one treatment zone that surrounds the center zone. The at least one treatment zone carries a large amount of high ADD or high plus power relative to the power in the center zone.
  • As illustrated in FIGS. 6a -b, the power profiles rise gradually and continuously from a margin of the center zone (point A) to a point within the at least one treatment zone (point B). In specific embodiments, the location of point B is between 3.0 mm and 4.5 mm from a center of the lens. The at least one treatment zone may remain constant from point B to a margin of an optic zone (point C, for example at 4.5 mm). As illustrated in FIG. 6c , the power profile may zig-zag or oscillate as the power rises from point A to point B and/or point C and does not need to be monotonic. In specific embodiments, the at least one treatment zone may have a dioptric power ranging from about +1 D to about +15 D.
  • According to the present invention, a gradual and/or periodic change of plus power in the at least one treatment zone mitigates the halo effect because such variations smoothen the intensity profile at sharp black and white edges. The halo intensity profiles of the three lens designs of FIGS. 6a-c are shown in FIGS. 7a -c, respectively. All three designs have a smooth halo intensity profile at the black/white edge.
  • While lenses of the present invention are designed so that the halo becomes less bothersome to the human eye, it may be difficult to reduce the halo effect when the lens becomes decentered on the eye. When a lens decenters, the ring-like structure in PSF becomes asymmetric, and energy will shift from one side of PSF to another side. As a result, one side of ring-like structure in PSF will have a much higher intensity, and the halo intensity will increase. The halo will become obvious regardless to the halo intensity profile. Hence, the utilized lens geometrical design should preferably result in good lens centration on the eye to further minimize potential for the visual artifacts.
  • With reference now to FIGS. 8a -c, the power profiles for three additional lens designs according to the present invention are illustrated. These three lens designs have 1) at least one enhanced treatment zone in which power is added within the center zone, and 2) at least one treatment zone. The at least one enhanced treatment zone may vary in diameter from about 0.5 mm to about 1.0 mm. The power magnitude of the at least one enhanced treatment zone may range from about +1 D (FIG. 8a ) to about +10 D (FIGS. 8b-c ). The at least one treatment zone have a gradual and/or period change in plus or ADD power as discussed above or may have a stepped increase in plus or ADD power. The power magnitude of the at least one treatment zone may range from about +5 D to about +15 D (FIGS. 8b-c ).
  • Referring now to FIG. 9, there is illustrated a schematic diagrammatic view of a contact lens 900 in accordance with an embodiment of the present invention. The contact lens 900 comprises an optic zone 902 and an outer zone 904. The optic zone 902 comprises a first, center zone 906 and at least one peripheral zone 908. In specific embodiments, the diameter of the optic zone 902 may be selected to be 8.0 mm, the diameter of the substantially circular first zone 906 may be selected to be 4.0 mm, and the boundary diameters of an annular outer peripheral zone 908 may be 5 mm and 6.5 mm as measured from the geometric center of the lens 900. It is important to note that FIG. 9 only illustrates an exemplary embodiment of the present invention. For example, in this exemplary embodiment, the outer boundary of the at least one peripheral zone 908 does not necessarily coincide with the outer margin of the optic zone 902, whereas in other exemplary embodiments, they may coincide. The outer zone 904 surrounds the optic zone 902 and provides standard contact lens features, including lens positioning and centration. In accordance with one exemplary embodiment, the outer zone 904 may include one or more stabilization mechanisms to reduce lens rotation when on eye.
  • It is important to note that the various zones in FIG. 9 are illustrated as concentric circles, the zones may comprise any suitable round or non-round shapes such as an elliptical shape.
  • It is important to note that as the entrance pupil size of the eye varies among subpopulations, in certain exemplary embodiments, the lens design may be customized to achieve both good foveal vision correction and myopic treatment efficacy based on the patient's average pupil size. Moreover, as pupil size correlates with refraction and age for pediatric patients, in certain exemplary embodiments, the lens may be further optimized towards subgroups of the pediatric subpopulation with specific age and/or refraction based upon their pupil sizes. Essentially, the power profiles may be adjusted or tailored to pupil size to achieve an optimal balance between foveal vision correction and minimization of halo effect resulting from a high plus or high ADD treatment zone.
  • Currently available contact lenses remain a cost effective means for vision correction. The thin plastic lenses fit over the cornea of the eye to correct vision defects, including myopia or nearsightedness, hyperopia or farsightedness, astigmatism, i.e. asphericity in the cornea, and presbyopia, i.e., the loss of the ability of the crystalline lens to accommodate. Contact lenses are available in a variety of forms and are made of a variety of materials to provide different functionality.
  • Daily wear soft contact lenses are typically made from soft polymer materials combined with water for oxygen permeability. Daily wear soft contact lenses may be daily disposable or extended wear disposable. Daily disposable contact lenses are usually worn for a single day and then thrown away, while extended wear or frequent replacement disposable contact lenses are usually worn for a period of up to thirty days. Colored soft contact lenses use different materials to provide different functionality. For example, a visibility tint contact lens uses a light tint to aid the wearer in locating a dropped contact lens, enhancement tint contact lenses have a translucent tint that is meant to enhance one's natural eye color, the color tint contact lens comprises a darker, opaque tint meant to change one's eye color, and the light filtering tint contact lens functions to enhance certain colors while muting others. Rigid gas permeable hard contact lenses are made from siloxane-containing polymers but are more rigid than soft contact lenses and thus hold their shape and are more durable. Bifocal contact lenses are designed specifically for patients with presbyopia and are available in both soft and rigid varieties. Toric contact lenses are designed specifically for patients with astigmatism and are also available in both soft and rigid varieties. Combination lenses combining different aspects of the above are also available, for example, hybrid contact lenses.
  • It is important to note that the lens designs of the present invention may be incorporated into any number of different contact lenses formed from any number of materials. Specifically, the lens design of the present invention may be utilized in any of the contact lenses described herein, including, daily wear soft contact lenses, rigid gas permeable contact lenses, bifocal contact lenses, toric contact lenses and hybrid contact lenses. In addition, although the invention is described with respect to contact lenses, it is important to note that the concept of the present invention may be utilized in spectacle lenses, intraocular lenses, corneal inlays and onlays.
  • In accordance with another exemplary embodiment, an ophthalmic lens comprises a center zone with high plus power as a myopic progression treatment zone. Once again, high plus power has the same meaning as high ADD power and does not necessarily result in a high positive power in the treatment zone as is the case, say, of vision correction of high hyperopia. Rather it refers to a difference in power between the treatment zone and the myopic vision correction zone that is higher than traditionally used for the reading addition powers classically used in bifocal, multifocal or progressive addition lenses for presbyopia. Referring to FIG. 10, there is illustrated a diagrammatic representation of a contact lens 1000 in accordance with this exemplary embodiment. The contact lens 1000 comprises an optic zone 1002 and an outer zone 1004. The optic zone 1002 comprises a center zone 1006 and a first peripheral zone 1008. In this exemplary embodiment, the center zone 1006 has a diameter that ranges from 0.50 mm to 4.0 mm with a power ranging from +5 diopters to +15 diopters. In other embodiments, the power can be lower, for example, +2.5 diopters and higher, for example +20 diopters. Also in this exemplary embodiment, the first peripheral zone 1008 has a negative power for myopic vision correction. In other words, the power to correct the individual's refractive error, myopia, resides in the first peripheral zone 1008 rather than in the center of the lens. The contact lens 1000 may include an additional plus powered concentric treatment zones 1010 outside of the first peripheral zone 1008. More specifically, the first peripheral zone 1008 which has the power to correct the refractive error is surrounded with plus power treatment zones. It is important to note that each of the treatment zones may have the same plus power or different plus powers. The diameter of the first peripheral zone 1008 and the one or more additional plus powered concentric treatment zones 1010 is selected to provide a balance between adequate vision and myopia control treatment. Additional exemplary zone diameters are illustrated in FIG. 10. It will be readily apparent to those skilled in the art that the peripheral zone diameters will be chosen depending on the diameter of the central zone to achieve a balance between obtaining adequate myopia control and satisfactory vision. For example, in a preferred embodiment, the diameter of the central zone is 1.0 mm, the outer diameter of the first peripheral zone is 4.2 mm, and the outer diameter of the second peripheral zone is 8.5 mm.
  • Referring to FIG. 11, there is illustrated a diagrammatic representation of a contact lens 1100 in accordance with another exemplary embodiment. The contact lens 1100 comprises an optic zone 1102 and an outer zone 1104. The optic zone 1102 comprises a center zone 1106 and a first peripheral zone 1108. In this exemplary embodiment, the center zone 1106 has a diameter that ranges from 0.50 mm to 4.0 mm with a power ranging from +5 diopters to +15 diopters. In other embodiments, the power may be lower, for example, +2.5 diopters and higher, for example, +20 diopters. Also in this exemplary embodiment, the first peripheral zone 1108 has a negative power for myopic vision correction. In other words, the power to correct the individual's refractive error, myopia, resides in the first peripheral zone 1108 rather than in the center of the lens. The contact lens 1100 may include one or more additional plus powered concentric treatment zones 1110 outside of the first peripheral zone 1108. More specifically, the first peripheral zone 1108 which has the power to correct the refractive error is surrounded with plus power treatment zones. It is important to note that each of the treatment zones may have the same plus power or different plus powers. Contact lens 1100 may include an additional negative power for myopic vision correction zone 1112. The diameter of the first peripheral zone 1108, the one or more additional plus powered concentric treatment zones 1110, and the additional negative power zone 1112 are selected to provide a balance between adequate vision and myopia control treatment. For this exemplary embodiment, refer to FIG. 11 for the range of diameters for the zones.
  • Various embodiments may include a center myopia progression treatment zone in combination with peripheral zones that may be utilized for refractive error correction and additional myopia progression treatment zones all within the peripheral region. Various combinations may be utilized outside of the center zone. Multiple concentric zones for myopic vision correction and treatment with different ADD powers may be added in the peripheral region of the optic zone with the zones so arranged to achieve a balance between myopic control treatment efficacy and adequate vision.
  • The myopia control efficacy of a multi-zone soft contact lens is believed to be related to several factors, including the power of the treatment zone, the size of the treatment zone relative to the entrance pupil, and the proximity of the treatment zone to the geometric center of the contact lens. The challenge of any myopia control treatment is to deliver a high myopia control effect while maintaining acceptable vision. The design of this exemplary embodiment maximizes the power of the treatment zone and the proximity of the treatment zone to the center of the lens while minimizing the size of the treatment zone relative to the entrance pupil to provide for acceptable vision. In other words, the contact lens of the present invention comprises a small diameter treatment zone of high plus power in the center of the lens. A number of experiments demonstrate the ability to have acceptable vision with these designs and are presented below.
  • Referring now to FIG. 12, there is illustrated a graphical representation of the loss in visual acuity, VA, in logMAR versus central zone size over four ADD powers for a 5.5 mm pupil size. This VA data was generated by introducing the optical designs to the eye. As may be seen from FIG. 12, minimizing the size of the treatment zone relative to the entrance pupil yields better results relative to the loss of VA. In addition, the data suggest that once a power of +5 diopters or greater is utilized, the rays passing through the treatment zones are sufficiently spread upon reaching the retina that loss in visual acuity is minimized.
  • FIG. 13 is a graphical representation of the loss in visual acuity versus central zone diameter in a lens with a center plus design having a +10 diopter power for both a 5.5 mm pupil and a 3.5 mm pupil. As illustrated, for a 5.5 mm diameter pupil, VA decreases as the size of the central plus zone increases. For a 5.5 mm diameter pupil, VA is lowered by 0.03+/−0.01, 0.05+/−0.04 and 0.06+/−0.05 logMAR for 1.0, 1.5 and 2.0 mm near zone diameters respectively. For a 3.5 mm diameter pupil, the VA is further decreased to 0.07 30 /−0.03, 0.08+/−0.04 and 0.14+/−0.01 logMAR compared to the baseline.
  • FIG. 14 is a graphical representation of the size of halo in degrees versus central diameter for both a 5.5 mm diameter pupil and a 3.5 mm diameter pupil. The halo data of a center plus design having a +10 diopter power was generated by introducing the optical designs to the eye and using purpose built methodologies to measure halo size and brightness. As illustrated, halo was not visible for center plus conditions for a 1.0 mm diameter central plus zone. For a 5.5 mm diameter pupil, the halo was detectable for both 1.5 and 2.0 mm diameter central zones, with halo sizes of 0.40+/−0.24 degrees and 0.73+/−0.22 degrees respectively. For a 3.5 mm diameter pupil, the halo was only detectable with a 2.0 mm central zone diameter with a halo size of 0.28+/−0.05 degrees. FIG. 15 is a graphical representation of the brightness of halo versus central zone diameter for both a 5.5 mm diameter pupil and a 3.5 mm diameter pupil. As illustrated, halo is not visible for center plus designs with a 1.00 mm diameter central plus zone. Halo is not detectable for a 1.5 mm center plus design for a 3.5 mm pupil diameter. For a 5.5 mm diameter pupil, the halo was detectable for 1.5 and 2.0 mm diameter central zones with brightness of 13.5+/−2.8 and 16.5+/−6.4 gray level respectively. For a 3.5 mm diameter pupil, the halo was only detectable with a 2.0 mm diameter central zone with a brightness of 15.5+/−2.8 gray level.
  • Similar VA and halo experiments may be utilized to allow for the designs of this exemplary embodiment to be optimized for the power, size, and location of the treatment zone(s) to provide acceptable vision.
  • It is important to note that various power profiles may be utilized in the center and one or more peripheral zones or regions of the optic zone. For example, in FIG. 16A, a center zone has a negative power for myopic vision correction, a first peripheral region has a high ADD, and a second peripheral zone has a negative power for myopic vision correction equal to the center zone. In FIG. 16B, the center zone has a high ADD, a first peripheral zone has a negative power for myopic vision correction, a second peripheral zone has a high ADD equal to the center zone and a third peripheral zone has a negative power for myopic vision correction equal to the first peripheral zone. In FIG. 16C, the center zone has a low Add, a first peripheral zone has a negative power for myopic vision correction, a second peripheral zone has a high ADD which is higher than the ADD in the center zone and a third peripheral zone has a negative power for myopic vision correction equal to the first peripheral zone. In FIG. 16D, a center zone has a high ADD, a first peripheral zone has a negative power for myopic vision correction, a second peripheral zone has a low ADD and a third peripheral zone has a negative power for myopic vision correction equal to the first peripheral zone. The important thing to understand is that any number of suitable variations may be utilized in accordance with the present invention, including low ADDs may be zero. In FIG. 16A through 16D, the y-axis power is relative to the negative power for myopic vision correction as is the case for FIG. 2, 6A, 6B, 6C, 8A, 8B, and 8C.
  • Although shown and described is what is believed to be the most practical and preferred embodiments, it is apparent that departures from specific designs and methods described and shown will suggest themselves to those skilled in the art and may be used without departing from the spirit and scope of the invention. The present invention is not restricted to the particular constructions described and illustrated, but should be constructed to cohere with all modifications that may fall within the scope of the appended claims.

Claims (7)

What is claimed is:
1. An ophthalmic lens for at least one of slowing, retarding or preventing myopia progression and minimizing halo effect, the ophthalmic lens comprising:
an optic zone, the optic zone including a center zone configured as a myopia progression treatment zone, the center zone comprising an ADD power of between +0.5 diopters and +20.0 diopters relative to the negative power required to correct myopia, and at least one peripheral zone surrounding the center zone, the at least one peripheral zone comprising a myopia vision correction region with a negative power for myopic vision correction; and
an outer zone surrounding the optic zone.
2. The ophthalmic lens according to claim 1, wherein the optic zone comprises one or more additional plus powered concentric myopia progression treatment zones outside of the at least one peripheral zone, the one or more additional plus powered concentric myopia progression treatment zones having an ADD power of between +0.5 diopters and +20.0 diopters.
3. The ophthalmic lens according to claim 1, wherein the optic zone comprises one or more additional myopic vision correction zones with a negative power for vision correction.
4. The ophthalmic lens according to claim 1, wherein the ophthalmic lens comprises a contact lens.
5. The ophthalmic lens according to claim 1, wherein the ophthalmic lens comprises a spectacle lens.
6. The ophthalmic lens according to claim 1, wherein the ophthalmic lens comprises an intraocular lens, a corneal inlay, or a corneal onlay.
11. The ophthalmic according to claim 1, further comprising one or more stabilization mechanisms in the outer zone.
US15/383,414 2014-08-20 2016-12-19 High plus center treatment zone lens design and method for preventing and/or slowing myopia progression Abandoned US20170115509A1 (en)

Priority Applications (14)

Application Number Priority Date Filing Date Title
US15/383,414 US20170115509A1 (en) 2014-08-20 2016-12-19 High plus center treatment zone lens design and method for preventing and/or slowing myopia progression
IL255609A IL255609A0 (en) 2016-12-19 2017-11-12 High plus center treatment zone lens design and method for preventing and/or slowing myopia progression
AU2017261563A AU2017261563B2 (en) 2016-12-19 2017-11-16 High plus center treatment zone lens design and method for preventing and/or slowing myopia progression
SG10201709641QA SG10201709641QA (en) 2016-12-19 2017-11-22 High plus center treatment zone lens design and method for preventing and/or slowing myopia progression
CA2989354A CA2989354C (en) 2016-12-19 2017-12-15 High plus center treatment zone lens design and method for preventing and/or slowing myopia progression
TW106144094A TWI767965B (en) 2016-12-19 2017-12-15 Ophthalmic lens for at least one of slowing, retarding or preventing myopia progression and minimizing halo effect
KR1020170173313A KR20180071177A (en) 2016-12-19 2017-12-15 High plus center treatment zone lens design and method for preventing and/or slowing myopia progression
BR102017027278-8A BR102017027278A2 (en) 2016-12-19 2017-12-18 higher center treatment zone lens configuration and method for preventing and / or slowing myopia progression
EP17208227.3A EP3336600A1 (en) 2016-12-19 2017-12-18 High plus center treatment zone lens design and method for preventing and/or slowing myopia progression
JP2017241480A JP2018101133A (en) 2016-12-19 2017-12-18 High plus center treatment zone lens design and method for preventing and/or slowing myopia progression
RU2017144173A RU2694777C2 (en) 2016-12-19 2017-12-18 Design of lens with central treatment area with high positive optical power and method for preventing and/or slowing progression of myopia
CN202311381706.2A CN117434748A (en) 2016-12-19 2017-12-19 High-decentration treatment zone lens design and method for preventing and/or slowing progression of myopia
CN201711381406.9A CN108205208A (en) 2016-12-19 2017-12-19 Height plus center treatment region lens design and the method for preventing and/or slowing down myopia progression
HK18114270.2A HK1255154A1 (en) 2016-12-19 2018-11-08 High plus center treatment zone lens design and method for preventing and/or slowing myopia progression

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US14/464,182 US9638936B2 (en) 2014-08-20 2014-08-20 High plus treatment zone lens design for preventing and/or slowing myopia progression
US15/383,414 US20170115509A1 (en) 2014-08-20 2016-12-19 High plus center treatment zone lens design and method for preventing and/or slowing myopia progression

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US14/464,182 Continuation-In-Part US9638936B2 (en) 2014-08-20 2014-08-20 High plus treatment zone lens design for preventing and/or slowing myopia progression

Publications (1)

Publication Number Publication Date
US20170115509A1 true US20170115509A1 (en) 2017-04-27

Family

ID=60673867

Family Applications (1)

Application Number Title Priority Date Filing Date
US15/383,414 Abandoned US20170115509A1 (en) 2014-08-20 2016-12-19 High plus center treatment zone lens design and method for preventing and/or slowing myopia progression

Country Status (13)

Country Link
US (1) US20170115509A1 (en)
EP (1) EP3336600A1 (en)
JP (1) JP2018101133A (en)
KR (1) KR20180071177A (en)
CN (2) CN108205208A (en)
AU (1) AU2017261563B2 (en)
BR (1) BR102017027278A2 (en)
CA (1) CA2989354C (en)
HK (1) HK1255154A1 (en)
IL (1) IL255609A0 (en)
RU (1) RU2694777C2 (en)
SG (1) SG10201709641QA (en)
TW (1) TWI767965B (en)

Cited By (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10092393B2 (en) 2013-03-14 2018-10-09 Allotex, Inc. Corneal implant systems and methods
EP3514613A1 (en) * 2018-01-22 2019-07-24 Johnson & Johnson Vision Care Inc. Ophthalmic lens with an optically non-coaxial zone for myopia control
US20190278106A1 (en) * 2014-08-20 2019-09-12 Johnson & Johnson Vision Care, Inc. High plus treatment zone lens design and method for preventing and/or slowing myopia progression
US10449090B2 (en) 2015-07-31 2019-10-22 Allotex, Inc. Corneal implant systems and methods
US10571717B2 (en) 2016-08-01 2020-02-25 University Of Washington Ophthalmic lenses for treating myopia
US10884264B2 (en) 2018-01-30 2021-01-05 Sightglass Vision, Inc. Ophthalmic lenses with light scattering for treating myopia
US10921612B2 (en) 2018-03-29 2021-02-16 Reopia Optics, Llc. Spectacles and associated methods for presbyopia treatment and myopia progression control
US11067832B2 (en) * 2018-03-01 2021-07-20 Essilor International Lens element
WO2021220006A1 (en) 2020-04-30 2021-11-04 Coopervision International Limited Myopia control lens and related methods
US20220179240A1 (en) * 2020-12-03 2022-06-09 Eyes Color Co., Ltd. Contact lens
WO2023059422A1 (en) * 2021-10-07 2023-04-13 Indizen Optical Technologies of America, LLC Ophthalmic lenses for myopia reduction
US11681162B2 (en) 2018-03-29 2023-06-20 Reopia Optics, Inc. Anti-myopia-progression spectacles and associated methods
US11718052B2 (en) 2017-05-08 2023-08-08 Sightglass Vision, Inc. Contact lenses for reducing myopia and methods for making the same
US11754859B2 (en) 2018-01-22 2023-09-12 Johnson & Johnson Vision Care, Inc Ophthalmic lens with an optically non-coaxial zone for myopia control
US11754858B2 (en) 2020-04-30 2023-09-12 Coopervision International Limited Multifocal ophthalmic lens and related methods
US11762220B2 (en) 2020-04-30 2023-09-19 Coopervision International Limited Multifocal ophthalmic lenses and related methods
US11789292B2 (en) 2018-01-22 2023-10-17 Johnson & Johnson Vision Care, Inc. Ophthalmic lens with an optically non-coaxial zone for myopia control
US11947197B2 (en) 2018-03-29 2024-04-02 Reopia Optics, Inc. Spectacles for presbyopia treatment and myopia progression control and associated methods

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220137432A1 (en) * 2020-11-04 2022-05-05 Bausch + Lomb Ireland Limited Ophthalmic lens including a peripheral zone having an add-power offset and a spatially-modulated optical parameter
US20220197060A1 (en) * 2020-12-18 2022-06-23 Coopervision International Limited Myopia-control contact lenses and methods relating thereto
CN115236877A (en) * 2021-04-22 2022-10-25 亮点光学股份有限公司 Myopia control contact lens
GB2623813A (en) * 2022-10-28 2024-05-01 Coopervision Int Ltd Myopia control contact lenses and methods

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4575205A (en) * 1984-10-15 1986-03-11 Rappazzo J Alan Self-adherent corneal contact lens
US5702440A (en) * 1996-01-26 1997-12-30 Allergan Multifocal ophthalmic lens for dim-lighting conditions
US6045578A (en) * 1995-11-28 2000-04-04 Queensland University Of Technology Optical treatment method
US20040169820A1 (en) * 2002-12-06 2004-09-02 Visx, Incorporated Presbyopia correction using patient data
US20100073629A1 (en) * 2007-05-21 2010-03-25 Menezes Edgar V Ophthalmic lenses for prevention of myopia progression
US20120062836A1 (en) * 2010-09-09 2012-03-15 Tse Yan Yin Method and system for retarding the progression of myopia
US20120194780A1 (en) * 2009-10-22 2012-08-02 Coopervision International Holding Company, Lp Contact Lens Sets And Methods To Prevent Or Slow Progression Of Myopia Or Hyperopia
US8480229B2 (en) * 2009-12-17 2013-07-09 Johnson & Johnson Vision Care, Inc. Method for stabilizing contact lenses
US20140211147A1 (en) * 2013-01-30 2014-07-31 Johnson & Johnson Vision Care, Inc. Asymmetric lens design and method for preventing and/or slowing myopia progression

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE452611T1 (en) 2003-11-19 2010-01-15 Vision Crc Ltd DEVICES FOR CHANGING THE RELATIVE CURRAVITY OF THE FIELD AND THE POSITIONS OF PERIPHERAL AXIS-SHIFTED FOCAL POSITIONS
US7832859B2 (en) * 2007-03-09 2010-11-16 Auckland Uniservices Limited Contact lens and method
US8684520B2 (en) * 2008-08-11 2014-04-01 Novartis Ag Lens design and method for preventing or slowing the progression of myopia
CN103097940B (en) * 2010-09-13 2016-02-03 香港理工大学 In order to slow down the method and system of myopia progression
KR20140074271A (en) 2011-06-15 2014-06-17 비져니어링 테크놀로지스, 인크. Method of treating myopia progressions
TWI626491B (en) * 2012-12-10 2018-06-11 布萊恩荷登視覺協會 Ophthalmic optical lens for vision correction having one or more areas of more positive power
US9638936B2 (en) * 2014-08-20 2017-05-02 Johnson & Johnson Vision Care, Inc. High plus treatment zone lens design for preventing and/or slowing myopia progression
US9625739B2 (en) * 2014-08-20 2017-04-18 Johnson & Johnson Vision Care, Inc. Pupil size-independent lens design and method for preventing and/or slowing myopia progression
US10061143B2 (en) * 2014-08-29 2018-08-28 Johnson & Johnson Vision Care, Inc. Multifocal lens design for preventing and/or slowing myopia progression
US20170336653A1 (en) * 2014-11-05 2017-11-23 Brien Holden Vision Institute Systems and Methods Involving Single Vision and Multifocal Lenses for Inhibiting Myopia Progression

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4575205A (en) * 1984-10-15 1986-03-11 Rappazzo J Alan Self-adherent corneal contact lens
US6045578A (en) * 1995-11-28 2000-04-04 Queensland University Of Technology Optical treatment method
US5702440A (en) * 1996-01-26 1997-12-30 Allergan Multifocal ophthalmic lens for dim-lighting conditions
US20040169820A1 (en) * 2002-12-06 2004-09-02 Visx, Incorporated Presbyopia correction using patient data
US20100073629A1 (en) * 2007-05-21 2010-03-25 Menezes Edgar V Ophthalmic lenses for prevention of myopia progression
US20120194780A1 (en) * 2009-10-22 2012-08-02 Coopervision International Holding Company, Lp Contact Lens Sets And Methods To Prevent Or Slow Progression Of Myopia Or Hyperopia
US8480229B2 (en) * 2009-12-17 2013-07-09 Johnson & Johnson Vision Care, Inc. Method for stabilizing contact lenses
US20120062836A1 (en) * 2010-09-09 2012-03-15 Tse Yan Yin Method and system for retarding the progression of myopia
US20140211147A1 (en) * 2013-01-30 2014-07-31 Johnson & Johnson Vision Care, Inc. Asymmetric lens design and method for preventing and/or slowing myopia progression

Cited By (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10092393B2 (en) 2013-03-14 2018-10-09 Allotex, Inc. Corneal implant systems and methods
US20190278106A1 (en) * 2014-08-20 2019-09-12 Johnson & Johnson Vision Care, Inc. High plus treatment zone lens design and method for preventing and/or slowing myopia progression
US20190278107A1 (en) * 2014-08-20 2019-09-12 Johnson & Johnson Vision Care, Inc. High plus treatment zone lens design and method for preventing and/or slowing myopia progression
US10823980B2 (en) * 2014-08-20 2020-11-03 Johnson & Johnson Vision Care, Inc. High plus treatment zone lens design and method for preventing and/or slowing myopia progression
US10838236B2 (en) * 2014-08-20 2020-11-17 Johnson & Johnson Vision Care, Inc High plus treatment zone lens design and method for preventing and/or slowing myopia progression
US10952900B2 (en) 2015-07-31 2021-03-23 Allotex, Inc. Corneal implant systems and methods
US10449090B2 (en) 2015-07-31 2019-10-22 Allotex, Inc. Corneal implant systems and methods
US10571717B2 (en) 2016-08-01 2020-02-25 University Of Washington Ophthalmic lenses for treating myopia
US11543681B2 (en) 2016-08-01 2023-01-03 University Of Washington Ophthalmic lenses for treating myopia
US11718052B2 (en) 2017-05-08 2023-08-08 Sightglass Vision, Inc. Contact lenses for reducing myopia and methods for making the same
EP3667402A1 (en) * 2018-01-22 2020-06-17 Johnson & Johnson Vision Care Inc. Ophthalmic lens with an optically non-coaxial zone for myopia control
TWI817981B (en) * 2018-01-22 2023-10-11 美商壯生和壯生視覺關懷公司 Ophthalmic lens with an optically non-coaxial zone
US10901237B2 (en) 2018-01-22 2021-01-26 Johnson & Johnson Vision Care, Inc. Ophthalmic lens with an optically non-coaxial zone for myopia control
US11768386B2 (en) 2018-01-22 2023-09-26 Johnson & Johnson Vision Care, Inc. Ophthalmic lens with an optically non-coaxial zone for myopia control
EP3514613A1 (en) * 2018-01-22 2019-07-24 Johnson & Johnson Vision Care Inc. Ophthalmic lens with an optically non-coaxial zone for myopia control
AU2019200257B2 (en) * 2018-01-22 2023-11-09 Johnson & Johnson Vision Care, Inc. Ophthalmic lens with an optically non-coaxial zone for myopia control
US11789292B2 (en) 2018-01-22 2023-10-17 Johnson & Johnson Vision Care, Inc. Ophthalmic lens with an optically non-coaxial zone for myopia control
US11754859B2 (en) 2018-01-22 2023-09-12 Johnson & Johnson Vision Care, Inc Ophthalmic lens with an optically non-coaxial zone for myopia control
US11914228B2 (en) 2018-01-30 2024-02-27 Sightglass Vision, Inc. Ophthalmic lenses with light scattering for treating myopia
US10884264B2 (en) 2018-01-30 2021-01-05 Sightglass Vision, Inc. Ophthalmic lenses with light scattering for treating myopia
US11067832B2 (en) * 2018-03-01 2021-07-20 Essilor International Lens element
US11947197B2 (en) 2018-03-29 2024-04-02 Reopia Optics, Inc. Spectacles for presbyopia treatment and myopia progression control and associated methods
US11681161B2 (en) 2018-03-29 2023-06-20 Reopia Optics, Inc. Anti-myopia-progression spectacles and associated methods
US11681162B2 (en) 2018-03-29 2023-06-20 Reopia Optics, Inc. Anti-myopia-progression spectacles and associated methods
US11187921B2 (en) 2018-03-29 2021-11-30 Reopia Optics, Llc. Anti-myopia-progression spectacles and associated methods
US10921612B2 (en) 2018-03-29 2021-02-16 Reopia Optics, Llc. Spectacles and associated methods for presbyopia treatment and myopia progression control
US11762220B2 (en) 2020-04-30 2023-09-19 Coopervision International Limited Multifocal ophthalmic lenses and related methods
US11754858B2 (en) 2020-04-30 2023-09-12 Coopervision International Limited Multifocal ophthalmic lens and related methods
US11934043B2 (en) 2020-04-30 2024-03-19 Coopervision International Limited Myopia control lens and related methods
WO2021220006A1 (en) 2020-04-30 2021-11-04 Coopervision International Limited Myopia control lens and related methods
US20220179240A1 (en) * 2020-12-03 2022-06-09 Eyes Color Co., Ltd. Contact lens
WO2023059422A1 (en) * 2021-10-07 2023-04-13 Indizen Optical Technologies of America, LLC Ophthalmic lenses for myopia reduction

Also Published As

Publication number Publication date
TW201837548A (en) 2018-10-16
CA2989354A1 (en) 2018-06-19
AU2017261563B2 (en) 2022-07-07
IL255609A0 (en) 2017-12-31
AU2017261563A1 (en) 2018-07-05
HK1255154A1 (en) 2019-08-09
TWI767965B (en) 2022-06-21
JP2018101133A (en) 2018-06-28
KR20180071177A (en) 2018-06-27
RU2694777C2 (en) 2019-07-16
CN108205208A (en) 2018-06-26
RU2017144173A (en) 2019-06-18
RU2017144173A3 (en) 2019-06-18
CN117434748A (en) 2024-01-23
CA2989354C (en) 2021-02-09
BR102017027278A2 (en) 2018-08-14
EP3336600A1 (en) 2018-06-20
SG10201709641QA (en) 2018-07-30

Similar Documents

Publication Publication Date Title
US10823980B2 (en) High plus treatment zone lens design and method for preventing and/or slowing myopia progression
CA2989354C (en) High plus center treatment zone lens design and method for preventing and/or slowing myopia progression
EP3514613B1 (en) Ophthalmic lens with an optically non-coaxial zone for myopia control
EP2988163B1 (en) Pupil size-independent lens design and method for preventing and/or slowing myopia progression
US11754859B2 (en) Ophthalmic lens with an optically non-coaxial zone for myopia control
US11789292B2 (en) Ophthalmic lens with an optically non-coaxial zone for myopia control

Legal Events

Date Code Title Description
AS Assignment

Owner name: JOHNSON & JOHNSON VISION CARE, INC., FLORIDA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:BRENNAN, NOEL A.;CHENG, XU;COLLINS, MICHAEL J.;AND OTHERS;SIGNING DATES FROM 20161201 TO 20170327;REEL/FRAME:043315/0465

STPP Information on status: patent application and granting procedure in general

Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER

STPP Information on status: patent application and granting procedure in general

Free format text: FINAL REJECTION MAILED

STPP Information on status: patent application and granting procedure in general

Free format text: ADVISORY ACTION MAILED

STPP Information on status: patent application and granting procedure in general

Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION

STPP Information on status: patent application and granting procedure in general

Free format text: NON FINAL ACTION MAILED

STPP Information on status: patent application and granting procedure in general

Free format text: FINAL REJECTION MAILED

STPP Information on status: patent application and granting procedure in general

Free format text: ADVISORY ACTION MAILED

STPP Information on status: patent application and granting procedure in general

Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION

STPP Information on status: patent application and granting procedure in general

Free format text: NON FINAL ACTION MAILED

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION